Zentalis Pharmaceuticals, Inc. (ZNTL)
Data as of , from SEC Form 4 filings.
Net insider buying (90d)Watch ZNTL
See up to 3 months of ZNTL. The 7-day demo opens the 1M and 3M ranges and puts ZNTL on your watchlist.
Start 7-day demoLatest ZNTL insider trades
About Zentalis Pharmaceuticals, Inc. (ZNTL)
Zentalis Pharmaceuticals, Inc. files with the SEC under CIK 0001725160 and is classified as pharmaceutical preparations. It is grouped with Health Care companies on this site.
ZNTL Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 1 | 4,335,000 | $15.17M |
| Grant or award | 1 | 9,727 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
ZNTL insider transactions (Form 4)
2318 Form 4 filings on record, the earliest from Oct 4, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Ingmar Bruns - Officer | Grant or award | Common Stock | 9,727 | $2.18 footnote F2 | $21K | |
| ||||||
| WALTERS GROUP - 10% Owner | Open-market purchase | Common Stock | 4,335,000 footnote F1 | $3.50 | $15.17M | |
| ||||||
| David Michael Johnson - Director | Grant or award | Common Stock | 57,100 footnote F1 | $0.00 | - | |
| ||||||
 Jan Skvarka - Director | Grant or award | Common Stock | 57,100 footnote F1 | $0.00 | - | |
| ||||||
| Luke Nathaniel Walker - Director | Grant or award | Common Stock | 57,100 footnote F1 | $0.00 | - | |
| ||||||
| Enoch Kariuki - Director | Grant or award | Common Stock | 57,100 footnote F1 | $0.00 | - | |
| ||||||
| Scott Dunseth Myers - Director | Grant or award | Common Stock | 57,100 footnote F1 | $0.00 | - | |
| ||||||
| Shannon Campbell - Director | Grant or award | Common Stock | 114,200 | $0.00 | - | |
| Ingmar Bruns - Officer | Open-market sale | Common Stock | 2,962 footnote F1 | $2.43 | $7K | |
| Ingmar Bruns - Officer | Open-market sale | Common Stock | 335 footnote F1 | $2.39 | $802 | |
| ||||||
| Vincent Vultaggio - Officer | Open-market sale | Common Stock | 29,951 footnote F1 | $2.43 | $73K | |
| Vincent Vultaggio - Officer | Open-market sale | Common Stock | 3,379 footnote F1 | $2.39 | $8K | |
| Vincent Vultaggio - Officer | Open-market sale | Common Stock | 6,894 footnote F2 | $2.42 | $17K | |
| ||||||
| Julia Marie Eastland - Officer | Open-market sale | Common Stock | 7,866 footnote F1 | $2.43 | $19K | |
| Julia Marie Eastland - Officer | Open-market sale | Common Stock | 889 footnote F1 | $2.39 | $2K | |
| ||||||
| Vincent Vultaggio - Officer | Open-market sale | Common Stock | 2,540 footnote F1 | $2.55 | $6K | |
| Vincent Vultaggio - Officer | Open-market sale | Common Stock | 556 footnote F2 | $2.52 | $1K | |
| ||||||
| WALTERS GROUP - 10% Owner | Open-market purchase | Common Stock | 6,459,973 footnote F1 | $1.20 | $7.75M | |
| ||||||
| James B. Bucher - Officer | Grant or award | Stock Option (Right to Buy) | 400,000 | $0.00 | - | |
| Ingmar Bruns - Officer | Grant or award | Stock Option (Right to Buy) | 712,650 | $0.00 | - | |
| Julia Marie Eastland - Officer | Grant or award | Stock Option (Right to Buy) | 3,028,800 | $0.00 | - | |
| Scott Dunseth Myers - Director | Grant or award | Common Stock | 260,192 | $0.00 | - | |
| Vincent Vultaggio - Officer | Open-market sale | Common Stock | 1,603 | $3.18 | $5K | |
Item 8.01, 9.01
Item 2.02, 7.01
Item 5.07
Item 5.02
ZNTL insider trading FAQ
What is the latest insider trade for ZNTL?
Zentalis Pharmaceuticals, Inc. (ZNTL) had 2 insider filings in the last 90 days, with the most recent on 2026-10-01. The full record for ZNTL runs to 18 Form 4 filings, the earliest from 2024-10-04. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ZNTL stock?
1 insider purchase of ZNTL was filed in the last 90 days, totaling $15.17M.
How many insiders are selling ZNTL stock?
No insider sales of ZNTL were filed in the last 90 days. 10 sales are on record for this company.
Where can I see ZNTL SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ZNTL Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Ingmar Bruns view on EDGAR
- - WALTERS GROUP view on EDGAR
- - David Michael Johnson view on EDGAR
- - Jan Skvarka view on EDGAR
- - Luke Nathaniel Walker view on EDGAR
- - Enoch Kariuki view on EDGAR
- - Scott Dunseth Myers view on EDGAR
- - Shannon Campbell view on EDGAR
- - Ingmar Bruns view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where ZNTL's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ZNTL with a 7-day demo
- ZNTL on your watchlist
- Every ZNTL Form 4 filing on record
- Up to 3 months of ZNTL price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
